Phenothiazine Derivatives: Treatment for Neurodegeneration
Lipid peroxidation resulting from oxidative stress is a crucial factor in the pathogenesis of many diseases, including neurodegenerative disorders, cardiovascular disease, asthma and diabetes. Phenothiazine derivatives are capable of reducing or preventing lipid peroxidation and therefore have potential therapeutic value for numerous disease states.
| Date added | 22 Jan 2008 |
|---|---|
| Reference number | 92-009 |
| Status | The patent application entered PCT stage in July 2007. |
| Availability | Licensing and co-development |
| References | [Blank] |
The technology and its advantages
Researchers at UCL have developed highly potent phenothiazine-derived antioxidant compounds that protect intact brain tissue from cell death induced by oxidative stress in vitro. These compounds have drug-like chemical characteristics and a low molecular weight that is potentially advantageous for crossing the blood-brain barrier. These compounds may also enhance the effects of known neuroprotective agents and may, therefore, be useful adjuvants for established therapies.
Market opportunity
Phenothiazine derivatives may prove of significant value in the treatment of a host of neurodegenerative conditions, as well as many other conditions involving oxidative stress beyond the central nervous system (CNS). They could be used in the manufacture of medicaments for:
• Neurodegenerative disorders, including Alzheimer’s disease, Huntington disease and multiple sclerosis
• Stroke (cerebral ischaemia), treatment of trauma to the CNS, or treatment of subsequent reperfusion injury
• Prevention of deafness due to exposure to excessive sound levels
• Disorders outside of the CNS, including cardiovascular disease (for example ischaemia), asthma and diabetes
Further information
Please contact: Dr. Carol Harty
UCL Business PLC
Tel +44 (0)20 7679 9000 Email c.harty@uclb.com
